Summary
R 61837 or 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine is a new and potent inhibitor of rhinoviruses at concentrations not inhibitory to HeLa cell growth. Different rhinovirus serotypes varied widely in their susceptibility to the antiviral agent. The MICs for 50% CPE reduction ranged from 0.004 to 15 µg/ml. The yields of the most susceptible serotypes were reduced by a factor of 1,000 to 10,000 after single round high multiplicity infections in presence of low concentrations of the compound. The inactivation of some but not all serotypes in a time-, concentration- and temperature-dependent way by R 61837 indicated a direct interaction between the drug and the viral particles. The antiviral activity of the compound was confirmed in the human target cells for rhinoviruses by experiments using nasal polyp explant cultures.
Keywords: HeLa Cell, Target Cell, Potent Inhibitor, Direct Interaction, Viral Particle
References
- 1.Al-Nakib W, Willman J, Higgins PG, Tyrrell DAJ, Shepherd WM, Freestone DS. Failure of intranasally administered 4′,6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol. 1987;92:255–260. doi: 10.1007/BF01317482. [DOI] [PubMed] [Google Scholar]
- 2.Al-Nakib W, Higgins PG, Tyrrell DAJ, Barrow IG, Taylor N, Andries K. Proceedings of the VIIth International Congress of Virology, Edmonton. Ottawa: National Research Council Canada; 1987. Tolerance and prophylactic efficacy of a new antirhinovirus compound, R 61837; p. 217. [Google Scholar]
- 3.Bauer DJ, Selway JWT, Batchelor JF, Tisdale M, Caldwell IC, Young DAB. 4′,6-dichloroflaven (BW 683 C), a new anti-rhinovirus compound. Nature. 1981;292:369–370. doi: 10.1038/292369a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Couch RB. The common cold: control? J Infect Dis. 1984;150:167–173. doi: 10.1093/infdis/150.2.167. [DOI] [PubMed] [Google Scholar]
- 5.Fox MP, Otto MJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986;30:110–116. doi: 10.1128/aac.30.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Groelke JW, Coalson JJ, Baseman JB. Growth requirements of ferret tracheal epithelial cells in primary culture. Proc Soc Exp Biol Med. 1985;179:309–317. doi: 10.3181/00379727-179-42102. [DOI] [PubMed] [Google Scholar]
- 7.hamory BH, Hendley JO, Gwaltney JM., Jr Rhinovirus growth in nasal polyp organ culture. Proc Soc Exp Biol Med. 1977;155:577–582. doi: 10.3181/00379727-155-39854. [DOI] [PubMed] [Google Scholar]
- 8.Hamparian VV, Colonno RJ, Cooney MK, Dick EC, Gwaltney JM, Hughes JH, Jordan WS, Kapikian AZ, Mogabgab WJ, Monto A, Phillips CA, Reuckert RR, Schieble JH, Stott EJ, Tyrrell DAJ. A collaborative report: Rhinoviruses—extension of the numbering system from 89 to 100. Virology. 1987;159:191–192. doi: 10.1016/0042-6822(87)90367-9. [DOI] [PubMed] [Google Scholar]
- 9.Ishitsuka H, Ninomya YN, Ohsawa C, Fujiu M, Suhura Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-410. Antimicrob Agents Chemother. 1982;22:617–621. doi: 10.1128/aac.22.4.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kenny MT, Dulworth JK, Bargar TM, Torney HL, Graham MC, Manelli AM. In vitro antiviral activity of the 6-substituted 2-(3′-4′-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610, MDL 20,646, and MDL 20,957. Antimicrob Agents Chemother. 1986;30:516–518. doi: 10.1128/aac.30.3.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ninomya Y, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-410, Ro 09-0179, RMI-15,731, 4′,6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother. 1985;27:595–599. doi: 10.1128/aac.27.4.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lechner JF, Haugen A, McClendon IA, Pettis EW. Clonal growth of normal adult human bronchial epithelial cells in a scrum-free medium. In Vitro. 1982;18:633–643. doi: 10.1007/BF02796396. [DOI] [PubMed] [Google Scholar]
- 13.Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA. In vitro activity of WIN51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1985;27:883–886. doi: 10.1128/aac.27.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Phillpotts RJ, Wallace J, Tyrrell DAJ, Freestone DS, Shepherd WM. Failure of oral 4′-6-dichloroflavan to protect against rhinovirus in man. Arch Virol. 1983;75:115–121. doi: 10.1007/BF01314131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DAJ, Lenox-Smith I. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J Antimicrob Chemother. 1984;14:403–409. doi: 10.1093/jac/14.4.403. [DOI] [PubMed] [Google Scholar]
- 16.Reed SE. The assessment of antirhinovirus compounds with clinical potential. In: Collier JH, Oxford J, editors. Developments in antiviral chemotherapy. London: Academic Press; 1980. pp. 157–172. [Google Scholar]
- 17.Selway JWT. Antiviral activity of flavones and flavans. Prog Clin Biol Res. 1986;213:521–526. [PubMed] [Google Scholar]
- 18.Tisdale M, Selway JWT. Effect of dichloroflavan (BW 683 C) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother. 1984;14(Suppl A):97–105. doi: 10.1093/jac/14.suppl_a.97. [DOI] [PubMed] [Google Scholar]
- 19.Zerial A, Werner GH, Phillpotts RJ, Willmann JS, Higgins PG, Tyrrell DAJ. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother. 1985;27:846–850. doi: 10.1128/aac.27.5.846. [DOI] [PMC free article] [PubMed] [Google Scholar]